Bernstein upgraded Novo Nordisk (NYSE:NVO) to “Market Perform” with a stock price of $84.86. The company’s stock shows slight ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

Novo Nordisk (0QIU – Research Report) received a Hold rating and a DKK600.00 price target from Bernstein analyst Florent Cespedes today. The ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The ...

Skuffende data for vægttabsmidlet Cagrisema sendte Novo Nordisk-aktien ned med 20,7 procent fredag Novo Nordisk-aktien styrdykkede med over 20 procent fredag efter offentliggørelsen af ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...